• Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright

    Source: Buzz FX / 25 Feb 2025 08:11:19   America/New_York


    Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright Written by MarketBeat February 25, 2025 Share Link copied to clipboard. Summit Therapeutics ( NASDAQ:SMMT - Get Free Report ) 's stock had its "buy" rating reaffirmed b
    Read more...
Share on,